Skip to main content

Table 1 Baseline patient demographic and disease characteristics

From: Assessing the outcomes of everolimus on renal angiomyolipoma associated with tuberous sclerosis complex in China: a two years trial

  Everlimus (N = 18)
Age in years, median (range) 29(20~ 46)
 < 30 year 9(50%)
 ≥ 30 year 9(50%)
Sex
 Women 12(66.7%)
 Men 6(33.3%)
Gene mutation
 TSC1 0(0%)
 TSC2 18(100%)
Diagnosis of lymphangioleiomyomatosis 6(33.3%)
Skin lesion(≥1) 18(100%)
Presence of subepedymal giant cell astrocytoma 1(5.6%)
Longest diameter of the largest renal angiomyolipoma lesion
 ≥ 8 cm 14(77.8%)
 ≥ 4 cm and < 8 cm 4(22.2%)
 < 4 cm 0(0%)
Sum of volumes of target renal angiomyolipoma lesions, cm3
 Mean (SD) 1974 (2406)
 Median (range) 1247 (60.77~ 9079)
Bilateral angiomyolipoma 16(88.9%)
Number of target angiomyolipoma lesions  
 1~ 2 11(61.1%)
 3~ 4 7(38.9%)
Previous angiomyolipoma therapy
 Surgery/invasive procedure 6(33.3%)
  Renal embolisation 2(11.1%)
  Partial nephrectomy 2(11.1%)
  Nephrectomy 2(11.1%)
 Medication 0(0%)